KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Change in Inventory (2016 - 2025)

Biomarin Pharmaceutical's Change in Inventory history spans 17 years, with the latest figure at $18.1 million for Q4 2025.

  • For the quarter ending Q4 2025, Change in Inventory fell 47.09% year-over-year to $18.1 million, compared with a TTM value of $116.9 million through Dec 2025, up 84.05%, and an annual FY2025 reading of $116.9 million, up 84.05% over the prior year.
  • Change in Inventory for Q4 2025 was $18.1 million at Biomarin Pharmaceutical, down from $26.3 million in the prior quarter.
  • The five-year high for Change in Inventory was $59.1 million in Q4 2023, with the low at -$18.2 million in Q3 2024.
  • Average Change in Inventory over 5 years is $22.0 million, with a median of $24.9 million recorded in 2021.
  • Year-over-year, Change in Inventory crashed 150.03% in 2021 and then surged 1557.98% in 2023.
  • Tracing BMRN's Change in Inventory over 5 years: stood at $15.9 million in 2021, then skyrocketed by 156.32% to $40.8 million in 2022, then soared by 44.72% to $59.1 million in 2023, then plummeted by 42.02% to $34.3 million in 2024, then plummeted by 47.09% to $18.1 million in 2025.
  • Per Business Quant, the three most recent readings for BMRN's Change in Inventory are $18.1 million (Q4 2025), $26.3 million (Q3 2025), and $48.1 million (Q2 2025).